Ferrario, C., Menda, Y., Esfahani, S. A., Keam, B., Thompson, A., Friedmann, J., Bodeker, K., Meador, C. B., Burks, H., Lu, D., Klein, K., Muelas, E. H., Salem, N., Fude-Blumer, T., Randolph, J., Chawla, R. (2026). Phase I study of [
                    <sup>225</sup>
                    Ac]Ac-ETN029, a DLL3-targeted radioligand therapy, in patients with advanced DLL3-expressing solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3174